SCHEMBL4766455

SCHEMBL4766455

CCOC(=O)c1cnc(Cl)c(N)c1NC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.46
KDM4E B2RXH2 5/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
ALDH1A1 P00352 6/20 0.44
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
CSNK1D P48730 1/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.42
DPP4 P27487 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062151 0.88 HSP90AA1 (0.48) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL15413264 0.86 KDM4E (0.45) KDM4ENPC1ALDH1A1KMT2AMEN1
SCHEMBL24866746 0.83 KDM4E (0.43) KDM4ENPC1ALDH1A1KMT2AMEN1
SCHEMBL31164464 0.83 KDM4E (0.43) KDM4ENPC1ALDH1A1KMT2AMEN1
SCHEMBL30064908 0.80 NPC1 (0.50) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL22208087 0.80 NPC1 (0.50) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL4104185 0.80 NPC1 (0.50) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL30065042 0.80 NPC1 (0.50) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL4766494 0.79 ALDH1A1 (0.46) HSP90AA1KDM4ENPC1RAB9AALDH1A1
SCHEMBL4072123 0.78 ALDH1A1 (0.57) KDM4ENPC1RAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008116816-A1 COMBINATION OF CB2 LIGAND AND PARACETAMOL GLAXO GROUP LIMITED (GB) 2008-10-02 WO disclosed
WO-2008116816-A1 COMBINATION OF CB2 LIGAND AND PARACETAMOL GLAXO GROUP LIMITED (GB) 2008-10-02 WO disclosed
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands GLAXO GROUP LIMITED 2008-09-11 US disclosed
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands GLAXO GROUP LIMITED 2008-09-11 US disclosed
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands GLAXO GROUP LIMITED 2008-09-11 US disclosed
EP-1912985-A1 IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2008-04-23 EP disclosed
WO-2007017237-A1 IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-02-15 WO disclosed
WO-2007017237-A1 IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands CNR1, CNR2, TRPV1 HSP90AA1 2792/4885KDM4E 2327/4885NPC1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.